Pannysylvania Magazine

(Albany, New York)- 5th Sep 2026 – DelveInsight’s latest report, “Glioblastoma Multiforme Market Insight, Epidemiology and Market Forecast – 2036,” provides a comprehensive analysis of the Glioblastoma Multiforme (GBM) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight’s estimates, the Glioblastoma Multiforme market size in the 7MM was approximately USD 900 million in 2025 and is projected to reach approximately USD 4,800 million by 2036, growing at a 13.2% CAGR during 2026–2036.

The growing burden of GBM, increasing clinical trial activity, advancements in targeted therapies and immunotherapies, development of cancer vaccines, and the emergence of innovative treatment approaches are expected to support significant market expansion during the forecast period.

Key Takeaways from the Glioblastoma Multiforme Market

• The Glioblastoma Multiforme market size in the 7MM was approximately USD 900 million in 2025 and is projected to reach USD 4,800 million by 2036, registering a 13.2% CAGR during the forecast period.

• The total number of Glioblastoma Multiforme incident cases in the 7MM was nearly 38,000 in 2025 and is projected to increase during the forecast period.

• The United States accounted for nearly 15,500 GBM incident cases in 2025.

• Approximately 60% of GBM cases in the United States were reported among men, highlighting a higher disease burden in males.

• The current standard of care generally involves maximally safe surgery followed by radiation therapy with concurrent and adjuvant temozolomide.

• Optune ± TMZ captured the highest revenue among current glioma therapies in the United States in 2025.

• Emerging approaches include cancer vaccines, CAR-T cell therapies, immune checkpoint inhibitors, oncolytic virotherapy, targeted therapies, and novel drug-delivery technologies.

• Key companies operating in the GBM landscape include Novocure, Roche/Genentech, Merck, Daiichi Sankyo, Novartis, Bayer, Avita Biomedical, TAE Life Sciences, Northwest Therapeutics, Advent BioServices, Orbus Therapeutics, TVAX Biomedical, Laminar Pharmaceuticals, Vigeo Therapeutics, Biohaven Pharmaceuticals, Eli Lilly and Company, Eisai, and others.

Keen to know more about the Glioblastoma Multiforme Market Report?https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market

Key Factors Driving the Glioblastoma Multiforme Market

Rising Incidence of Glioblastoma Multiforme

The increasing incidence of Glioblastoma Multiforme, one of the most aggressive and fatal forms of brain cancer, is expected to remain a major factor supporting market growth. DelveInsight estimates that the 7MM recorded nearly 38,000 incident GBM cases in 2025, with the patient burden expected to increase during the forecast period.

Advancements in Targeted Therapies and Immunotherapies

Rapid progress in precision medicine, targeted therapies, CAR-T cell therapies, immune checkpoint inhibitors, cancer vaccines, and gene therapies is transforming the GBM treatment landscape. Research efforts are increasingly focused on improving survival outcomes and overcoming the limitations associated with existing treatment approaches.

Increasing Clinical Trial Activities

The GBM pipeline is witnessing considerable clinical development activity involving novel therapeutics, combination strategies, cancer vaccines, and innovative drug-delivery technologies. Several investigational therapies are progressing through mid- and late-stage clinical development, creating opportunities for future market expansion.

Growing Adoption of Advanced Diagnostic Technologies

Advancements in neuroimaging, molecular diagnostics, genomic profiling, and biomarker-based testing are improving tumor classification, diagnosis, and personalized treatment planning. These developments are expected to support more targeted approaches to GBM management.

Expanding Use of Combination Therapies

The increasing use of multimodal treatment strategies combining surgery, radiation therapy, chemotherapy, tumor treating fields, and emerging immunotherapies is expected to contribute to market growth. The complex nature of GBM continues to drive research toward combination approaches capable of addressing multiple disease mechanisms.

Competitive Landscape

The Glioblastoma Multiforme treatment landscape includes established therapies as well as a robust pipeline of emerging candidates. Marketed and approved therapies include OPTUNE GIO, AVASTIN, TEMODAR/TEMODAL, TAFINLAR + MEKINIST, STIVARGA, and other treatment options.

Among emerging therapies, AV-GBM-1 from Aivita Biomedical/TAE Life Sciences is being evaluated as a personalized dendritic cell-based immunotherapy in newly diagnosed GBM. Eflornithine from Orbus Therapeutics is being investigated in combination with temozolomide, while LAM561 (2-OHOA) from Laminar Pharmaceuticals and Dordaviprone (ONC201) from Chimerix represent additional pipeline opportunities.

Other companies actively involved in the market include Northwest Therapeutics, TVAX Biomedical, Vigeo Therapeutics, Biohaven Pharmaceuticals, Bayer, Daiichi Sankyo, Novartis, Merck, Roche/Genentech, and Eisai, among others.

Discover more about the Glioblastoma Multiforme Market Landscape:DelveInsight – Glioblastoma Multiforme Market Report

Recent Developments in the Glioblastoma Multiforme Market

• July 2026: Northwest Biotherapeutics presented updated Phase III data for its personalized glioblastoma vaccine DCVax-L at the BNOS meeting. Analyses using advanced statistical matching reported a median survival advantage of up to 6.3 months and supported the company’s ongoing UK regulatory application.

• July 2026: Laminar Pharma announced that the final patient completed the last visit in the pivotal Phase 2b/3 trial of LAM561 in newly diagnosed glioblastoma, marking completion of the active clinical monitoring phase.

• June 2026: Knoa Pharma and the Global Coalition for Adaptive Research announced the first newly diagnosed GBM patient had been randomized to the tinostamustine arm of the Phase 2/3 GBM AGILE master protocol, while the first recurrent patient had been dosed.

• May 2026: BioLineRx and Hemispherian announced new preclinical data for GLIX1, an orally administered, brain-penetrating small molecule being evaluated for recurrent or progressive GBM.

• May 2026: Northwestern University initiated a clinical trial evaluating immune-modulating agents in GBM patients using the SonoCloud-9 device in combination with balstilimab, botensilimab, and liposomal doxorubicin.

• May 2026: Centre Antoine Lacassagne announced the PAZOGLIO Phase I/II study evaluating pazopanib in combination with temozolomide in newly diagnosed GBM following surgery and radiochemotherapy.

What is Glioblastoma Multiforme?

Glioblastoma Multiforme (GBM) is a highly aggressive and fast-growing primary brain cancer. It is often located in the cerebrum and is characterized by extensive local invasion of normal brain tissue, although it rarely spreads to organs outside the brain.

GBM can be classified into primary and secondary GBM. Primary GBM develops de novo without evidence of a less malignant precursor, whereas secondary GBM develops from initially lower-grade diffuse astrocytoma or anaplastic astrocytoma.

Diagnosis generally involves neurological examination followed by imaging techniques such as MRI, CT, and MR spectroscopy, with surgical biopsy used to establish the diagnosis.

Current Treatment Landscape

Treatment of GBM generally involves a multimodal approach. Surgery is typically performed to achieve maximum safe resection while preserving neurological function. This is generally followed by radiation therapy and chemotherapy, particularly temozolomide.

For recurrent disease, treatment options may include repeat surgery in selected patients, repeat chemoradiation, anti-angiogenic therapies such as bevacizumab, tumor treating field therapy, and enrollment in clinical trials.

Despite advances in understanding GBM biology, treatment remains challenging because of the blood-brain barrier, immunosuppressive tumor microenvironment, high recurrence rates, and limited effectiveness of available therapies.

Glioblastoma Multiforme Epidemiology Segmentation

The Glioblastoma Multiforme epidemiology analysis covers:

• Total Glioblastoma Multiforme Incident Cases

• Gender-specific Incident Cases

• Type-specific Incident Cases

• Incident Cases based on Primary Site

• Age-specific Incident Cases

• Incident Cases based on Histologic Classification

• Unmethylation of the MGMT Gene Promoter Cases

• BRAF V600E Mutation Cases

• Line-wise Treated Patient Pool

According to DelveInsight, the 7MM recorded nearly 38,000 GBM incident cases in 2025, while the United States accounted for approximately 15,500 cases. Primary GBM cases in the United States were estimated at nearly 14,000 in 2025.

Scope of the Glioblastoma Multiforme Market Report

• Study Period: 2022–2036

• Historical Year: 2022–2025

• Forecast Period: 2026–2036

• Base Year: 2026

• Geographies Covered: United States, Germany, France, Italy, Spain, United Kingdom, and Japan

• Market CAGR: 13.2% (2025–2036)

• Market Segmentation: Region/Geographies and Drugs/Therapies

• Epidemiology Segmentation: Total incident cases, gender, type, primary site, age, histologic classification, MGMT promoter unmethylation, BRAF V600E mutation, and line-wise treated pool

• Key Market Assessments: Addressable patient population, market drivers/barriers, pricing assumptions, KOL views, SWOT analysis, reimbursement, conjoint analysis, and unmet needs.

To know more about the clinical trials, emerging therapies, and therapeutic assessment of the Glioblastoma Multiforme market:View the Glioblastoma Multiforme Market Report

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Methodology

6. Market Overview

7. Clinical Landscape

8. Disease Background

9. Types

10. Molecular Classification

11. Causes

12. Signs and Symptoms

13. Diagnosis

14. Current Treatment Landscape

15. Unmet Needs

16. Patient Journey

17. Epidemiology

18. Epidemiology Forecast

19. Marketed Therapies

20. Emerging Therapies

21. Competitive Landscape

22. Market Access and Reimbursement

23. Market Forecast

24. Market Drivers and Barriers

25. SWOT Analysis

26. KOL Views

27. Appendix

28. Methodology

29. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/